Skip to content
Menu

Metagenomi Therapeutics, Inc. MGX

Full chart Compare
Set alert

Price alert · MGX

All alert types
0.61 USD -0.02 (-3.28%)

As ofNov 19, 2026, 3:38 PM EST

0.61 Day range 0.6423
0.60 52-week range 1.87
YTD
-62.28%
1 year
-62.04%

5D -0.0960 (-13.45%)

0.60000.65000.70000.7500FriMonTueWedThu0.6180
Market cap
23.10M
Revenue (ttm)
55.08M
Profit margin
-134.27%
EPS (ttm)
-2.50
Shares out
37.42M
Forward P/E
-1.38
YTD return
-62.28%
1-year return
-62.04%
Volume
111.80K
Avg volume
163.39K
Open
0.63
Previous close
0.6318
Day's range
0.61 – 0.6423
52-week range
0.60 – 1.87
Analysts
Strong Buy
Price target
18.40 (+2911.0%)

Key statistics

50-day average
2.31
200-day average
4.77
Enterprise value
-76.95M
Price / sales
2.72
Price / book
0.59
Revenue growth
-6.90%
Free cash flow
-73.89M
Total cash
274.59M
Total debt
46.07M
Return on equity
-30.34%
Short % of float
1.00%

Fundamental scorecard

4 of 25 checks passed on MGX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 0 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
MGX Revenue — quarterly 2.18M
MGX Net income — quarterly -21.13M
MGX EPS — quarterly -0.56

Earnings

MGX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 13, 2024Sep 1, 2024-0.70-0.45+0.25+35.71%
Aug 14, 2024Jun 1, 2024-0.59———
Aug 14, 2024Jun 1, 2024-0.59-0.29+0.30+50.85%
May 14, 2024Mar 1, 2024-0.95———
May 14, 2024Mar 1, 2024-0.95-1.19-0.24-25.26%

Upgrades / downgrades

MGX analyst upgrades and downgrades
DateFirmActionFromTo
Dec 10, 2024HC Wainwright & Co.mainBuyBuy
Nov 21, 2024HC Wainwright & Co.reitBuyBuy
Nov 20, 2024Chardan CapitalmainBuyBuy
Oct 15, 2024HC Wainwright & Co.reitBuyBuy
Sep 6, 2024HC Wainwright & Co.reitBuyBuy
Sep 5, 2024Chardan CapitalmainBuyBuy

About Metagenomi Therapeutics, Inc.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on MGX — it syncs with the Stock Master app.

Insider holders

MGX insider holders
InsiderRelationLatest transactionDateShares held
BAYER HEALTHCARE L.L.C.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 12, 20240
BORGES LUISOfficerStock Award(Grant)Mar 31, 202469,316
DELANEY SIMRENOfficerStock Award(Grant)Mar 31, 202493,892
HARNEST SIMONOfficerStock Award(Grant)Mar 31, 2024122,664
IRISH JIAN PH.D.PresidentStock Award(Grant)Mar 31, 2024655,898
NOONBERG SARAH BOfficerStock Award(Grant)Mar 31, 2024100,374

Institution ownership

MGX institution ownership
Holder% heldSharesValueReported
Novo Holdings A/S4.81%1,800,0007.22MSep 29, 2024
RA Capital Management, L.P.3.49%1,305,2395.23MSep 29, 2024
Farallon Capital Management LLC2.82%1,057,2014.24MSep 29, 2024
Pfm Health Sciences, Lp2.76%1,034,0024.15MSep 29, 2024
Citadel Advisors Llc2.15%804,4623.23MSep 29, 2024
HHLR Advisors, LTD2.08%777,7683.12MSep 29, 2024

Fund ownership

MGX fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund0.47%177,208710.60KSep 29, 2024
iShares Russell 2000 ETF0.44%163,172654.32KOct 30, 2024
Vanguard Extended Market Index Fund0.38%141,338566.76KSep 29, 2024
Fidelity Extended Market Index Fund0.38%142,625571.93KOct 30, 2024
Bridgeway Funds Inc-Ultra Small Company Market Fund0.25%92,200369.72KSep 29, 2024
Fidelity Small Cap Index Fund0.17%63,604255.05KAug 30, 2024